Table 2.

Univariate and multivariate analysis of clinicopathological factors associated with overall survival and cumulative recurrence

Factor	Overall survival		Cumulative recurrence
	HR (95% CI)	P value	HR (95% CI)	P value
Univariate analysis
Sex (male vs female)	0.733 (0.475 to 1.132)	0.161	0.988 (0.638 to 1.529)	0.955
Age, years (≥ 53 vs < 53)	1.350 (0.867 to 2.103)	0.184	1.194 (0.766 to 1.861)	0.434
Serum CA19-9 (< 37 vs ≥ 37, ng/mL)	0.852 (0.532 to 1.425)	0.532	0.892 (0.564 to 1.384)	0.485
AFP (≥ 20 vs < 20, ng/mL)	0.826 (0.426 to 1.602)	0.571	1.080 (0.555 to 2.103)	0.820
TNM stage (III/IV vs I/II)	1.605 (1.038 to 2.482)	0.033	1.557 (1.008 to 2.404)	0.046
Tumor differentiation (III/IV vs I/II)	1.042 (0.641 to 1.695)	0.867	0.823 (0.506 to 1.339)	0.433
Microvascular invasion (yes vs no)	1.759 (1.089 to 2.841)	0.021	1.765 (1.081 to 2.882)	0.023
Maximal tumor size (< 5 vs ≥ 5, cm)	1.081 (0.653 to 1.791)	0.762	1.158 (0.695 to 1.929)	0.574
Tumor number (single vs multiple)	0.983 (0.491 to 1.968)	0.961	0.915 (0.456 to 1.835)	0.802
Lymphatic metastasis (yes vs no)	1.636 (1.040 to 2.573)	0.033	1.769 (1.120 to 2.794)	0.014
SBP1 staining (high vs low)	0.377 (0.230 to 0.619)	0.001	0.551 (0.339 to 0.897)	0.016
Multivariate analysis
TNM stage (III/IV vs I/II)	1.839 (1.169 to 2.894)	0.008	1.528 (0.974 to 2.397)	0.065
Microvascular invasion (yes vs no)	1.004 (0.618 to 1632)	0.986	1.607 (0.971 to 2.659)	0.065
Lymphatic metastasis (yes vs no)	1.640 (1.029 to 2.613)	0.038	1.896 (1.193 to 3.014)	0.007
SBP1 staining (high vs low)	0.375 (0.226 to 0.623)	0.001	0.532 (0.323 to 0.877)	0.013

Univariate and multivariate analysis: Cox proportional hazards regression model. AFP alpha-fetoprotein, CA19-9 carbohydrate antigen 19-9, TNM tumor-node-metastasis, CI confidence interval, HR hazard ratio.